GLYXAMBI 25/5MG 10S

About

GLYXAMBI 25/5MG is a combination oral medication containing Empagliflozin (an SGLT2 inhibitor) and Linagliptin (a DPP-4 inhibitor). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin works by increasing glucose excretion in the urine, while Linagliptin enhances glucose-dependent insulin secretion and suppresses glucagon secretion by inhibiting the breakdown of incretin hormones.

This dual mechanism of action provides complementary benefits in managing blood sugar levels. Empagliflozin offers additional advantages such as cardiovascular and renal protection, while Linagliptin has a low risk of hypoglycemia when used alone and does not require dose adjustment for renal impairment. The combination offers comprehensive glycemic control and addresses multiple pathophysiological pathways involved in type 2 diabetes, making it a powerful option for patients needing enhanced therapy.

Uses

• Improvement of glycemic control in adults with type 2 diabetes mellitus.
• Used when diet and exercise alone are insufficient.
• Combines two distinct mechanisms for blood sugar reduction.
• Part of a comprehensive diabetes management plan.

Directions For Use

Take one tablet orally once daily in the morning, with or without food. Swallow the tablet whole with water.

Benefits

• Provides comprehensive blood glucose control.
• Combines cardiovascular and renal benefits of Empagliflozin.
• Low risk of hypoglycemia (when not combined with sulfonylurea/insulin).
• Convenient once-daily dosing with two active ingredients.
• No dose adjustment needed for Linagliptin component in renal impairment.
• Helps achieve HbA1c targets effectively.

Side Effects

• Urinary tract infections (UTIs)
• Genital mycotic infections
• Nasopharyngitis
• Increased urination
• Headache
• Dizziness
• Hypotension
• Pancreatitis (rare)
• Ketoacidosis (rare)
• Joint pain (arthralgia)
• Hypoglycemia (especially with sulfonylurea or insulin)
• Thirst

Safety Measures

• Alcohol - Excessive alcohol intake can increase the risk of ketoacidosis and dehydration (due to Empagliflozin) and affect blood sugar levels. Limit alcohol consumption.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development from Empagliflozin.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if components are excreted in human milk and could pose a risk to the infant.
• Liver - No dose adjustment is required for patients with hepatic impairment for either component.
• Kidney - Not recommended for patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease due to the Empagliflozin component.
• Lung - No specific contraindications or significant interactions related to lung conditions are typically noted for GLYXAMBI.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.